Abstract:Alport syndrome is a hereditary glomerular disease caused by mutation in the COL4A3, COL4A4, or COL4A5 gene encoding type IV collagen alpha 3, alpha 4, and alpha 5 chains (alpha 3-alpha 5(IV)), respectively, which are components of the glomerular basement membrane (GBM). The most common mutations are those in COL4A5, which comprise more than 80% of AS-associated mutations. Mutant achains cannot form alpha 345(IV) trimer, which leads to abnormal GBM. In current therapeutic approaches for the management of Alport syndrome, inhibitors of the renin angiotensin system (RAS) are typically prescribed. Although early intervention by RAS blockade suppresses the progression of nephritis, patients with Alport syndrome taking RAS inhibitor eventually develop end-stage renal disease. Numerous basic studies have revealed the molecules that are associated with the progression of Alport syndrome. However, candidate drug targets have not been assessed in clinical applications, and a novel therapeutic strategy is urgently needed. We have established collagen alpha 345(IV) heterotrimer formation assay system that is amenable to high throughput screening (HTS) by using split luciferase compliment system (NanoLucTM) (Omachi, et al., Cell Chem. Biol. 2018). The assay provided evidence that compared with wild-type alpha 345(IV) trimer, the heterotrimer with mutant alpha 5(IV) had either intracellular trimerization defect or trimer secretion defect. We have started screening of natural compounds in our original library using alpha 5(IV) G1244D-expressing cellular system, and are trying to find potential candidate compounds to correct the mutant alpha 5(IV)-dependent defect of alpha 345 (IV) trimer secretion. Furthermore, we will also discuss the recent progress on the generation of new Alport mouse models with missense mutations in C57BL/6 and 129 strains that may be usable for future analysis of the in vivo efficacy of our candidate compounds.

Alport Syndrome: a Unified Classification of Genetic Disorders of Collagen IV Alpha 345: a Position Paper of the Alport Syndrome Classification Working Group

Four novel mutations identified in the COL4A3, COL4A4 and COL4A5 genes in 10 families with Alport syndrome

Alport syndrome and Alport kidney diseases – elucidating the disease spectrum

Pharmacological approach and diagnosis for Alport syndrome

Advances and Unmet Needs in Genetic, Basic and Clinical Science in Alport Syndrome: Report from the 2015 International Workshop on Alport Syndrome.

The 2014 International Workshop on Alport Syndrome

Genotype-Phenotype Correlations for Pathogenic COL4A3–COL4A5 Variants in X-Linked, Autosomal Recessive, and Autosomal Dominant Alport Syndrome

Pathological diagnosis of Alport syndrome

Alport syndrome: Expanding diagnosis and treatment

Alport Syndrome With a Rare Collagen Type IV Alpha-4 (COL4A4) Gene Mutation: A Case Report

Renal, Auricular, and Ocular Outcomes of Alport Syndrome and Their Current Management

Novel Mutations In Col4a3, Col4a4, And Col4a5 In Chinese Patients With Alport Syndrome

A comprehensive review of Alport syndrome: definition, pathophysiology, clinical manifestations, and diagnostic considerations

Identification of a Novel COL4A5 Mutation in a Chinese Family with X-linked Alport Syndrome Using Exome Sequencing.

Genotype–Phenotype Correlations in Alport Syndrome—A Single-Center Experience

A Novel Mutation of COL4A3 Presents a Different Contribution to Alport Syndrome and Thin Basement Membrane Nephropathy

Genetic diagnosis of Alport syndrome in 16 Chinese families

A Clinicopathological Study of Alport Syndrome and Detection of Type IV Collagen Chains in Alport Patients.

Expert Consensus Guidelines for the Genetic Diagnosis of Alport Syndrome

A Novel COL4A5 Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease

The challenges and views in precise diagnosis and treatment of Alport syndrome